Huaxia Ophthalmology (301267): Steady increase in revenue and profit, and the M&A Juxin-1 epitaxial expansion logic is gradually being implemented
Huaxia Ophthalmology (301267): Steady growth in performance, acceleration of epitaxial mergers and acquisitions
Huaxia Ophthalmology (301267): Dominant disciplines lead growth, and the implementation of epitaxial mergers and acquisitions is expected to increase annual performance
Huaxia Ophthalmology (301267): In-vitro hospital integration and implementation continues to improve the national layout
Huaxia Ophthalmology (301267): Performance is in line with expectations, and epitaxial mergers and acquisitions are about to be implemented
Huaxia Ophthalmology (301267): The 24Q1 performance growth rate has slowed, and the implementation of mergers and acquisitions is expected to increase annual results
Huaxia Ophthalmology (301267): Steady growth in performance, endogenous extension improving national layout
Huaxia Ophthalmology (301267): The 24Q1 results are in line with expectations and the acquisition of hospitals will increase performance
Huaxia Ophthalmology (301267): 1Q24 steady growth service network continues to expand
Dongguan Securities released a research report on April 25 stating that Huaxia Ophthalmology (301267.SZ) was given a purchase rating. The main reasons for the rating include: 1) the core business has maintained rapid growth; 2) all domestic regions have a
Huaxia Ophthalmology (301267): Continuing to advance the “endogenous growth+epitaxial merger and acquisition” strategy
Huaxia Ophthalmology (301267): Steady increase in revenue and profit, balanced development of consumer medicine and serious medical care
Huaxia Ophthalmology (301267): From coastal to inland, the prospects for the national layout are improving
Huaxia Ophthalmology (301267): Steady increase in revenue and profit, balanced development of consumer medicine and serious medical care
Huaxia Ophthalmology (301267): Building a Highland of Talent and Technology, and Steady Advancement of National Expansion
Huaxia Ophthalmology (301267) 2023 Third Quarter Report Review: Performance Meets Expectations, Endogenous Growth, and Dual Wheel Drive for Epitaxial M&A
Huaxia Ophthalmology (301267) review: 3Q23 performance is in line with expectations and accelerates epitaxial expansion
Huaxia Ophthalmology (301267): Equilibrium growth between basic eye diseases and consumer ophthalmology, rich industrial funds, hospital reserves
Huaxia Ophthalmology (301267): Increased profit levels accelerate the “endogenous growth+epitaxial mergers and acquisitions” two-wheel drive strategy
Huaxia Ophthalmology (301267): Steady growth in performance and acceleration of extrapolated mergers and acquisitions
No Data